{
    "title": "To amend title XVIII of the Social Security Act to promote public notification and provide incentives to reduce drug shortages, and for other purposes.",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Patient Access to Drugs in Shortage \nAct of 2012''.\n\nSEC. 2. MARKET STABILITY INCENTIVES.\n\n    (a) Medicare.--\n            (1) In general.--Section 1847A(b) of the Social Security \n        Act (42 U.S.C. 1395w-3a(b)) is amended--\n                    (A) in paragraph (1), in the matter preceding \n                subparagraph (A), by striking ``paragraph (7)'' and \n                inserting ``paragraphs (7) and (9)''; and\n                    (B) by adding at the end the following new \n                paragraph:\n            ``(9) Sterile injectable products with 3 or fewer active \n        manufacturers.--\n                    ``(A) In general.--The payment amount for a drug \n                described in subparagraph (B) that is furnished on or \n                after July 1, 2013, and before January 1, 2020, shall \n                be equal to--\n                            ``(i) in the case of a drug described in \n                        subparagraph (B)(i), the volume-weighted \n                        wholesale acquisition cost determined under \n                        subparagraph (C) for the drug; and\n                            ``(ii) in the case of a drug described in \n                        subparagraph (B)(ii), the wholesale acquisition \n                        cost (as defined in subsection (c)) of the \n                        drug.\n                    ``(B) Drug described.--\n                            ``(i) In general.--A drug described in this \n                        subparagraph is a sterile injectable drug \n                        product that is manufactured by 3 or fewer \n                        active manufacturers (as determined by the \n                        Secretary) and is--\n                                    ``(I) a multiple source drug (as \n                                described in subsection (c)(6)(C)) for \n                                which there is no period of exclusivity \n                                in effect or available under section \n                                505(j), 505A, or 527 of the Federal \n                                Food, Drug, and Cosmetic Act; or\n                                    ``(II) a single source drug (as \n                                described in subsection (c)(6)(D)(ii)) \n                                for which there is no period of \n                                exclusivity in effect or available \n                                under section 505(c), 505A, or 527 of \n                                the Federal Food, Drug, and Cosmetic \n                                Act.\n                            ``(ii) Sterile injectable drug defined.--In \n                        this paragraph, the term `sterile injectable \n                        drug' means a drug approved by the Food & Drug \n                        Administration that is injected into the body.\n                    ``(C) Use of volume-weighted average wholesale \n                acquisition costs for multiple source drugs.--The \n                volume-weighted average wholesale acquisition costs \n                under this paragraph shall be determined under this \n                subparagraph in the same manner as the volume-weighted \n                average of the average sales prices is determined under \n                paragraph (6) except that, for purposes of this \n                paragraph, any reference in such paragraph (6) to the \n                average sale prices for a drug is deemed a reference to \n                wholesale acquisition cost (as defined in subsection \n                (c)(6)(B)) for the drug.''.\n            (2) HOPD prospective payment system.--Section 1833(t)(14) \n        of the Social Security Act (42 U.S.C. 1395l(t)(14)) is \n        amended--\n                    (A) in subparagraph (A)(iii), in the matter \n                preceding subclause (I), by striking ``subparagraph \n                (E)'' and inserting ``subparagraphs (E) and (I)''; and\n                    (B) by adding at the end the following new \n                subparagraph:\n                    ``(I) Sterile injectable products with 3 or fewer \n                active manufacturers.--The amount of payment for a drug \n                described in section 1847A(b)(9)(B) that is furnished \n                on or after July 1, 2013, and before January 1, 2020, \n                shall be equal to--\n                            ``(i) in the case of a drug described in \n                        clause (i) of such section, the volume-weighted \n                        wholesale acquisition costs amount determined \n                        under section 1847A(b)(9)(C) for the drug; and\n                            ``(ii) in the case of a drug described in \n                        clause (ii) of section 1847A(b)(9)(B), the \n                        wholesale acquisition cost (as defined in \n                        section 1847A(c)) of the drug.''.\n    (b) Medicaid.--\n            (1) In general.--Section 1927(a) of the Social Security Act \n        (42 U.S.C. 1396r-8(a)) is amended by adding at the end the \n        following new paragraph:\n            ``(8) Sterile injectable products with 3 or fewer active \n        manufacturers.--\n                    ``(A) In general.--Paragraph (1) of this subsection \n                and section 1903(i)(10)(A) shall not apply to a drug \n                that is described in section 1847A(b)(9)(C), that is \n                furnished on or after July 1, 2013, and before January \n                1, 2020, and for which payment may be made under part B \n                of title XVIII.\n                    ``(B) Guidance.--Not later than July 1, 2013, the \n                Secretary shall publish guidance on the exclusion of \n                certain sterile injectable products under subparagraph \n                (A).''.\n            (2) Conforming amendment.--Section 1903(i)(10)(A) of the \n        Social Security Act (42 U.S.C. 1396b(i)(10)(A)) is amended by \n        striking ``unless section 1927(a)(3) applies'' and inserting \n        ``unless paragraph (3) or (9) of section 1927(a) applies''.\n    (c) 340B Program.--\n            (1) In general.--Section 340B of the Public Health Service \n        Act (42 U.S.C. 256b) is amended by inserting after subsection \n        (e) the following:\n    ``(f) Exclusion of Certain Sterile Injectable Products.--\n            ``(1) In general.--For purposes of this section (including \n        with respect to the prohibition described in subsection \n        (a)(5)(L)(iii)), the term `covered outpatient drug' shall not \n        include a drug that is described in section 1847A(b)(9)(C) of \n        the Social Security Act, that is furnished on or after July 1, \n        2013, and before January 1, 2020, and for which payment may be \n        made under part B of title XVIII of such Act.\n            ``(2) Guidance.--Not later than July 1, 2013, the Secretary \n        shall publish guidance on the exclusion of certain sterile \n        injectable products under paragraph (1).''.\n    (d) Study and Report.--\n            (1) In general.--The Secretary of Health and Human Services \n        shall contract with an independent entity to study the effects \n        of the amendments made by this section on patient access to \n        sterile injectable products.\n            (2) Report.--As a condition of the contract described under \n        paragraph (1), the independent entity shall agree to submit to \n        Congress and such Secretary, not later than 3 years after the \n        date of enactment of this Act, a report that describes the \n        results of the study conducted under paragraph (1).\n\nSEC. 3. EXCLUSION OF BRANDED PRESCRIPTION DRUGS FROM ANNUAL FEE DURING \n              PERIODS OF SHORTAGE.\n\n    (a) In General.--Subsection (e) of section 9008 of the Patient \nProtection and Affordable Care Act is amended by redesignating \nparagraph (4) as paragraph (5) and by inserting after paragraph (3) the \nfollowing new paragraph:\n            ``(4) Exclusion during shortage.--The term `branded \n        prescription drug sales' shall not include sales of any branded \n        prescription drug that--\n                    ``(A) is on the drug shortage list maintained under \n                section 506E of the Federal Food, Drug, and Cosmetic \n                Act (21 U.S.C. 356e), and\n                    ``(B)(i) is the listed drug (as defined in section \n                505(j)(2)(A)(i) of the Federal Food, Drug, and Cosmetic \n                Act (21 U.S.C. 355(j)(2)(A)(i)) for a drug for which \n                the approval of an application under section 505(j) of \n                such Act (21 U.S.C. 355(j)) is in effect, or\n                    ``(ii) is the reference product (as defined in \n                section 351(i) of the Public Health Service Act (42 \n                U.S.C. 262(i)) for a biological product for which the \n                approval of an application under section 351(k) of such \n                Act (42 U.S.C. 262(j)) is in effect.''.\n    (b) Effective Date.--The amendment made by subsection (a) shall \napply to sales after the date of the enactment of this Act."
}